On June 24, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable with surgery or radiation.
Uncertainty prevails in times of crisis. Patients with cancer are all too familiar with the initial uncertainty surrounding a cancer diagnosis, treatments, and adjusting to a new normal. Oncology nurses are seeing parallels with the COVID-19 coronavirus pandemic as people worldwide face the unknowns of a health threat and the economic aftermath of the outbreak. Medical caregivers are confronting it head on as they work together to protect and tend to the physical and psychosocial needs of others.
Patients with cancer who contracted the COVID-19 coronavirus had high rates of 30-day all-cause mortality that was associated with general risk factors and risk factors unique to cancer, according to findings from one of the first data registry reports of patients with the dual diagnoses. The results were published in Lancet.
The 2019–2022 ONS Research Agenda mentions LGBTQ patients with cancer among ONS’s research priorities for the very first time. A panel discussion at the 44th Annual ONS Congress focused on this underrepresented patient population, so we are making progress. In the past few years, our field has given a little more attention to LGBTQ patients with cancer, although I suspect that many of the issues are still pervasive.
On June 22, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio®) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
Viral infections such as HIV may increase a person’s risk for developing several malignancies. However, most investigational drug studies exclude HIV-positive patients with cancer and optimal treatment regimens remain unknown.
Along with many other healthcare organizations, including ONS, last week the American Nurses Association (ANA) took a bold stand against racism, calling it a public health crisis. On June 12, 2020, ANA President Earnest Grant shared how racism is embedded in health care and what nurses should do to end it.
Get to know Kristin Ferguson, DNP, RN, OCN®, treasurer on the ONS Board of Directors from 2019–2021 and director-at-large from 2019–2022. Kristin is the clinical operations manager/nurse manager III at MedStar Georgetown University Hospital Lombardi Comprehensive Cancer Center in Washington, DC.
Like most nurses, my shifts as a new nurse functioned as consistently as clockwork. I would begin my afternoon shift by reviewing the assignment list. The previous shift’s nurses would handoff the patients, and I would head out to the unit to report to my assistive personnel and review the patients’ medication administration records. Every hour was dedicated to a different task, including my dinner break. That is, until a monumental moment jostled me from my systematic routine.
On June 18, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik™), an EZH2 inhibitor, for adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, who have received at least two prior systemic therapies and have no satisfactory alternative treatment options.